Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Up 27.7% in January

Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the target of a large increase in short interest in January. As of January 15th, there was short interest totalling 141,200 shares, an increase of 27.7% from the December 31st total of 110,600 shares. Approximately 0.7% of the company’s stock are sold short. Based on an average daily trading volume, of 95,500 shares, the short-interest ratio is currently 1.5 days.

Institutional Trading of Aileron Therapeutics

A number of large investors have recently bought and sold shares of the business. University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Aileron Therapeutics during the second quarter worth approximately $4,925,000. KG&L Capital Management LLC acquired a new position in Aileron Therapeutics in the 3rd quarter valued at $46,000. Sigma Planning Corp raised its position in Aileron Therapeutics by 68.3% during the 3rd quarter. Sigma Planning Corp now owns 212,410 shares of the company’s stock worth $752,000 after buying an additional 86,185 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Aileron Therapeutics by 34.8% in the 3rd quarter. Geode Capital Management LLC now owns 229,817 shares of the company’s stock worth $814,000 after acquiring an additional 59,370 shares during the period. Institutional investors and hedge funds own 90.89% of the company’s stock.

Aileron Therapeutics Price Performance

Aileron Therapeutics has a 52 week low of $1.61 and a 52 week high of $7.42. The company has a fifty day moving average price of $2.52 and a 200 day moving average price of $2.80.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).